2. Search Result
Search Result
Results for "

amyloid β-peptide (Aβ1-40)

" in MedChemExpress (MCE) Product Catalog:

606

Inhibitors & Agonists

2

Screening Libraries

24

Fluorescent Dyes

7

Biochemical Assay Reagents

187

Peptides

37

Inhibitory Antibodies

67

Natural
Products

36

Recombinant Proteins

15

Isotope-Labeled Compounds

32

Antibodies

3

Click Chemistry

10

Oligonucleotides

3

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P1363A
    β-Amyloid (1-42), human
    20+ Cited Publications

    amyloid β-peptide (1-42) (human)

    		 Amyloid-β Neurological Disease
    β-Amyloid (1-42) (Amyloid β-peptide (1-42)), human, a 42-amino acid peptide that has not been treated with HFIP, is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human, after being monomericized by HFIP and dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4 °C, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37 °C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death .
    β-Amyloid (1-42), human
  • HY-P1363
    β-Amyloid (1-42), human TFA
    20+ Cited Publications

    amyloid β-peptide (1-42) (human) TFA

    		 Amyloid-β Neurological Disease
    β-Amyloid (1-42) (Amyloid β-peptide (1-42), human TFA, a 42-amino acid peptide that has not been treated with HFIP, is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human TFA remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human TFA, after being monomericized by HFIP and dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4 °C, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37 °C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death .
    β-Amyloid (1-42), human TFA
  • HY-P0128
    β-Amyloid (25-35)
    Maximum Cited Publications
    42 Publications Verification

    amyloid beta-peptide (25-35); Aβ25-35; β-amyloid peptide (25-35)

    		 Amyloid-β Neurological Disease
    β-Amyloid (25-35) (Amyloid beta-peptide (25-35)) is the fragment Aβ(25-35) of the Alzheimer's amyloid β-peptide, has shown neurotoxic activities in cultured cells .
    β-Amyloid (25-35)
  • HY-P1388
    β-Amyloid (1-42), (rat/mouse)
    5+ Cited Publications

    amyloid β-peptide (1-42) (rat/mouse)

    		 Amyloid-β Neurological Disease
    β-Amyloid (1-42), (rat/mouse) is a 42-aa peptide, shows cytotoxic effect on acute hippocampal slices, and used in the research of Alzheimer's disease.
    β-Amyloid (1-42), (rat/mouse)
  • HY-P1362
    β-Amyloid (42-1), human
    1 Publications Verification

    amyloid β peptide (42-1)(human)

    		 Amyloid-β Neurological Disease
    β-Amyloid (42-1), human is the inactive form of Amyloid β Peptide (1-42). Its active form, β-Amyloid (1-42), may play a key role in the pathogenesis of Alzheimer's disease .
    β-Amyloid (42-1), human
  • HY-P1363F3
    5-FAM-β-Amyloid (1-42), human Tris

    5-FAM-amyloid β-peptide (1-42) (human) Tris

    		 Amyloid-β Neurological Disease
    5-FAM-β-Amyloid (1-42), human (5-FAM-Amyloid β-peptide (1-42) (human) TFA is a5-FAM labeled β-Amyloid (1-42), human TFA (HY-P1363).
    5-FAM-β-Amyloid (1-42), human Tris
  • HY-P0265A
    β-Amyloid (1-40) (human) TFA

    amyloid β-peptide (1-40) (human) TFA; Aβ40 (human) TFA; Aβ(1-40) (human) TFA

    		 Amyloid-β Neurological Disease
    β-Amyloid (1-40) TFA is a primary protein in plaques found in the brains of patients with Alzheimer's disease .
    β-Amyloid (1-40) (human) TFA
  • HY-P0128A
    β-Amyloid (25-35), HFIP-treated
    Maximum Cited Publications
    42 Publications Verification

    amyloid beta-peptide (25-35), HFIP-treated; Aβ25-35, HFIP-treated; β-amyloid peptide (25-35), HFIP-treated

    		 Amyloid-β Neurological Disease
    β-Amyloid (25-35) (Amyloid beta-peptide (25-35)), HFIP-treated is a β-Amyloid (25-35) (HY-P0128) treated with HFIP. β-Amyloid (25-35) (Amyloid beta-peptide (25-35)) is the fragment Aβ(25-35) of the Alzheimer's amyloid β-peptide, has shown neurotoxic activities in cultured cells .
    β-Amyloid (25-35), HFIP-treated
  • HY-P990109
    Aducanumab (Mouse IGG2a)

    		Amyloid-β Neurological Disease
    Aducanumab (Mouse IGG2a) is a monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ). The variable region of Aducanumab (Mouse IGG2a) is consistent with that of Aducanumab (HY-P9967), while the constant region is of Mouse IGG2a sequence. Aducanumab (Mouse IGG2a) has strong selectivity for Aβ fibrils with EC50s of >1 μM and 0.2 nM for monomeric Aβ1-40 and fibrillar Aβ1-42, respectively. Aducanumab (Mouse IGG2a) can be used for Alzheimer's disease (AD) research .
    Aducanumab (Mouse IGG2a)
  • HY-P99317
    Solanezumab

    LY-2062430

    		 Amyloid-β Neurological Disease
    Solanezumab (LY-2062430) is a humanized monoclonal IgG1 antibody directed against the mid-domain of the amyloid-β (Aβ) peptide. Solanezumab binds to the mid-domain of monomeric amyloid-beta to slow brain amyloid accumulation. Solanezumab can be used for the research of Alzheimer’s disease .
    Solanezumab
  • HY-P1363F1
    Biotin-β-Amyloid (1-42), human TFA

    Biotin-amyloid β-peptide (1-42) (human) TFA

    		 Amyloid-β Neurological Disease
    Biotin-β-Amyloid (1-42), human TFA (Biotin-Amyloid β-Peptide (1-42) (human) TFA) is the botin labeled β-Amyloid (1-42), human TFA (HY-P1363). β-Amyloid (1-42), human TFA is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease .
    Biotin-β-Amyloid (1-42), human TFA
  • HY-126192
    Pittsburgh Compound B

    PiB; 6-OH-BTA-1

    		 Amyloid-β Neurological Disease
    Pittsburgh Compound B (PiB) is a blood-brain barrier-permeable, specific Aβ deposition PET tracer that binds to Aβ(1-40) fibrils with a Ki value of 678.4 nM. Through click chemical modification (a clickable Pittsburgh Compound B derivative is prepared by introducing a PEG3 linker and an alkynyl group at the 6-hydroxy site of Pittsburgh Compound B, followed by covalent conjugation with azide-labeled fluorescent dyes or affinity tags via copper-catalyzed azide-alkyne cycloaddition (CuAAC)), Pittsburgh Compound B and its conjugates can be used for fluorescence imaging, ultrastructural studies, and enrichment and characterization of Aβ complexes. Pittsburgh Compound B is applicable to Alzheimer's disease research .
    Pittsburgh Compound B
  • HY-P1388A
    β-Amyloid (1-42), (rat/mouse) TFA
    5+ Cited Publications

    amyloid β-peptide (1-42) (rat/mouse) TFA

    		 Amyloid-β Neurological Disease
    β-Amyloid (1-42), (rat/mouse) TFA is a 42-aa peptide, shows cytotoxic effect on acute hippocampal slices, and used in the research of Alzheimer's disease.
    β-Amyloid (1-42), (rat/mouse) TFA
  • HY-P1466
    β-Amyloid (1-16)

    amyloid β-Protein (1-16)

    		 Amyloid-β Neurological Disease
    β-Amyloid (1-16) is a β-Amyloid protein fragment involved in metal binding. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.
    β-Amyloid (1-16)
  • HY-P99358
    Dezamizumab

    GSK 2398852; Anti-Serum amyloid P/SAP Reference Antibody (dezamizumab)

    		 Complement System Inflammation/Immunology
    Dezamizumab (GSK 2398852) is a fully humanized clonal IgG1 antibody against serum amyloid P component (SAP) with complement activation and amyloid clearance-inducing activities. Dezamizumab binds to SAP associated with amyloid deposits to form complexes that activate complement and mediate phagocytic clearance, triggering activation of the classical complement pathway. Dezamizumab can be used for the research of systemic amyloidosis .
    Dezamizumab
  • HY-P10605
    GSK3β-peptide

    		Akt GSK-3 Cancer
    GSK3β-peptide is a substrate mimetic peptide of glycogen synthase kinase 3-β (GSK3-β) that can bind to the active site of GSK3-β and mimic the behavior of a real substrate. GSK3β-peptide can be used to develop substrate mimetic inhibitors of Akt as potential anticancer drugs .
    GSK3β-peptide
  • HY-P4882A
    (Pyr3)-Amyloid β-Protein (3-42) TFA

    		Amyloid-β Neurological Disease
    (Pyr3)-Amyloid β-Protein (3-42) TFA is the predominant amyloid β-peptide structure deposited in human brain of Alzheimer's disease and Down's syndrome patients. (Pyr3)-Amyloid β-Protein (3-42) TFA is suggested to accumulate in the brain and to trigger the formation of insoluble amyloid β-peptide deposits .
    (Pyr3)-Amyloid β-Protein (3-42) TFA
  • HY-P3688A
    β-Amyloid (1-38) TFA

    Aβ (1-38) TFA; Aβ38 TFA

    		 Amyloid-β Neurological Disease
    β-Amyloid (1-38) (Aβ (1-38)) TFA is a β-Amyloid (Aβ) peptide. β-Amyloid (1-38) TFA interferes with the conversion of Aβ(1-42) to a β-sheet-rich aggregate. β-Amyloid (1-38)TFA reverses the negative impact of Aβ(1-42) on long-term potentiation in acute hippocampal slices and on membrane conductance in primary neurons, and mitigates an Aβ(1-42) phenotype in Caenorhabditis elegans .
    β-Amyloid (1-38) TFA
  • HY-P1903
    β-Amyloid (35-42)

    		Amyloid-β Neurological Disease
    β-Amyloid (35-42) is a peptide consisting of amino acid of 35 to 42 of beta amyloid protein.
    β-Amyloid (35-42)
  • HY-P1962
    β-Secretase inhibitor

    [Asn670, Sta671, Val672]-amyloid β peptide (662-675)

    		 Beta-secretase Neurological Disease
    β-Secretase inhibitor ([Asn670, Sta671, Val672]-Amyloid β Peptide (662-675)) is a β-secretase and BACE1 inhibitor (IC50: 25 nM for β-secretase) .
    β-Secretase inhibitor
  • HY-P1387
    β-Amyloid (1-40) (rat)

    		Amyloid-β Apoptosis Neurological Disease
    β-Amyloid (1-40) (rat) is a rat form of the amyloid β-peptide, which accumulates as an insoluble extracellular deposit around neurons, giving rise to the senile plaques associated with Alzheimer's disease (AD). β-Amyloid (1-40) (rat) increases 45Ca 2+ influx, induces neurodegeneration in the rat hippocampal neurons of the CA1 subfield. β-Amyloid (1-40) (rat) induces apoptosis. β-Amyloid (1-40) (rat) can be used for the research of Alzheimer's disease .
    β-Amyloid (1-40) (rat)
  • HY-P1362F
    Cy5-β-Amyloid (42-1), human Tris

    Cy5-amyloid β peptide (42-1)(human) Tris

    		 Amyloid-β Neurological Disease
    Cy5-β-Amyloid (42-1), human is a Cy5 fluorescently-labelled β-Amyloid (42-1, human) peptide (λex= 633 nm and λem= 670 nm) .
    Cy5-β-Amyloid (42-1), human Tris
  • HY-P1046
    β-Amyloid (1-15)

    amyloid β-Protein (1-15)

    		 Amyloid-β Neurological Disease
    β-Amyloid (1-15) is a fragment of β-Amyloid peptide. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.
    β-Amyloid (1-15)
  • HY-150049
    γ-Secretase modulator 13

    		Amyloid-β Neurological Disease
    γ-Secretase modulator 13 (compound 4) is a gamma-secretase modulator (GSMs) that inhibits the production of the aggregated amyloid β-peptide Aβ42 with an IC50 value of 163 nM. γ-Secretase modulator 13 can be used in the study of Alzheimer's disease .
    γ-Secretase modulator 13
  • HY-P4882
    (Pyr3)-Amyloid β-Protein (3-42)

    		Amyloid-β Neurological Disease
    (Pyr3)-Amyloid β-Protein (3-42) is the predominant amyloid β-peptide structure deposited in human brain of Alzheimer's disease and Down's syndrome patients. (Pyr3)-Amyloid β-Protein (3-42) is suggested to accumulate in the brain and to trigger the formation of insoluble amyloid β-peptide deposits .
    (Pyr3)-Amyloid β-Protein (3-42)
  • HY-P4885
    Glp-amyloid-β (3-40) peptide (human)

    AβpE3-40

    		 Amyloid-β Neurological Disease
    Glp-Amyloid-β (3-40) Peptide (human) (AβpE3-40) is a minor amounts of pyroglutamate-modified Aβ isolated from from 24-month-old Amyloid precursor protein (APP) transgenic Mice .
    Glp-amyloid-β (3-40) peptide (human)
  • HY-P1468
    β-Amyloid (1-28)

    amyloid β-Protein (1-28)

    		 Amyloid-β Neurological Disease
    β-Amyloid (1-28) is a β-Amyloid protein fragment involved in metal binding. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.
    β-Amyloid (1-28)
  • HY-P1363S
    β-Amyloid-15N (1-42), human TFA

    amyloid β-peptide-15N (1-42) (human) TFA

    		 Amyloid-β Neurological Disease
    β-Amyloid- 15N (1-42), human (TFA) is the 15N-labledβ-Amyloid (1-42) (TFA). β-Amyloid (1-42), human TFA (Amyloid β-Peptide (1-42) (human) TFA) is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease .
    β-Amyloid-15N (1-42), human TFA
  • HY-171348
    Amyloid-β-IN-2

    		Amyloid-β γ-secretase Neurological Disease
    Amyloid-β-IN-2 (Compound EX.112) is a selective γ-secretase inhibitor. Amyloid-β-IN-2 inhibits Aβ42 secretion in H4 cells with an EC50 value of 226 nM. Amyloid-β-IN-2 is promising for research of Alzheimer's disease (AD) and other diseases related to Aβ deposition .
    Amyloid-β-IN-2
  • HY-P2549
    Biotin-β-Amyloid (1-40)

    		Fluorescent Dye Neurological Disease
    Biotin-β-Amyloid (1-40) is a N-terminal-labelled biotinylated amyloid-β-(1-40) peptide.
    Biotin-β-Amyloid (1-40)
  • HY-P1517
    β-Amyloid (31-35)

    		Amyloid-β Neurological Disease
    β-Amyloid (31-35) is the shortest sequence of native Amyloid-β peptide that retains neurotoxic activity.
    β-Amyloid (31-35)
  • HY-126047
    (S)-(-)-Anatabine

    		NF-κB Beta-secretase Neurological Disease
    (S)-(-)-Anatabine is an NFκB/BACE-1 inhibitor with blood-brain barrier penetration. (S)-(-)-Anatabine inhibits NFκB activation via phosphorylation of its p65 subunit. (S)-(-)-Anatabine inhibits BACE-1 transcription and reduces BACE-1 protein levels. (S)-(-)-Anatabine lowers production of Aβ1-40 and Aβ1-42 by reducing β-cleavage of amyloid precursor protein without affecting α-cleavage. (S)-(-)-Anatabine can be used for the research of Alzheimer's disease .
    (S)-(-)-Anatabine
  • HY-P3779
    Amyloid 17-42

    Aβ(17-42)

    		 Apoptosis Neurological Disease
    Amyloid 17-42 (Aβ(17-42)) is a major constituent of diffuse plaques in Alzheimer's disease and cerebellar pre-amyloid in Down's syndrome, derived by alpha- and gamma-secretase cleavage of the amyloid precursor protein (APP). Amyloid 17-42 can induce neuronal apoptosis via a Fas-like/caspase-8 activation pathway .
    Amyloid 17-42
  • HY-P3780
    Cys-Gly-Lys-Lys-Gly-Amyloid β-Protein (36-42)

    		Amyloid-β Neurological Disease
    Cys-Gly-Lys-Lys-Gly-Amyloid β-Protein (36-42) is the 36-42 fragment of Amyloid β-Protein. β-amyloid, a polypeptide made up of 36-43 amino acids, is the main component of amyloid plaques found in the brains of people with Alzheimer's disease. β-amyloid oligomers (Aβos) plays A key role in the progression of Alzheimer's disease (AD) by inducing neuronal damage and cognitive impairment .
    Cys-Gly-Lys-Lys-Gly-Amyloid β-Protein (36-42)
  • HY-153416
    QR-0217

    		Amyloid-β Neurological Disease
    QR-0217 is a potent Aβ1-40 aggregation inhibitor with an IC50 value of 7.5 µM. QR-0217 inhibits α-synuclein aggregation. QR-0217 reduces memory impairments caused by Aβ neurotoxicity .
    QR-0217
  • HY-P4886A
    Amyloid β-Protein (3-42) TFA

    		Amyloid-β Neurological Disease
    Amyloid β-Protein (3-42) TFA is a precursor of Pyr peptide. Pyroglutamic acid-modified Aβ (pEAβ) (3-42) is the core of the amyloid plaque in Alzheimer's disease. pEAβ (3-42) accelerates the aggregation of Aβ(1-42), while Aβ(1-42) significantly slows down the primary and secondary nucleation of pEAβ(3-42).
    Amyloid β-Protein (3-42) TFA
  • HY-P3688
    β-Amyloid (1-38)

    Aβ (1-38); Aβ38

    		 Amyloid-β Neurological Disease
    β-Amyloid (1-38) (Aβ (1-38)) is a β-Amyloid (Aβ) peptide. β-Amyloid (1-38) interferes with the conversion of Aβ(1-42) to a β-sheet-rich aggregate. β-Amyloid (1-38) reverses the negative impact of Aβ(1-42) on long-term potentiation in acute hippocampal slices and on membrane conductance in primary neurons, and mitigates an Aβ(1-42) phenotype in Caenorhabditis elegans .
    β-Amyloid (1-38)
  • HY-P1388F
    FITC-Ahx-β-Amyloid (1-42), (rat/mouse) tris

    FITC-Ahx-amyloid β-peptide (1-42) (rat/mouse) tris

    		 Amyloid-β Neurological Disease
    FITC-Ahx-β-Amyloid (1-42), (rat/mouse) (tris) is a fluorescently labeled (FITC) form of β-Amyloid (1-42), (rat/mouse) (HY-P1388), which can be used in Alzheimer's disease-related research, such as aggregation, fiber formation, cellular uptake or imaging experiments. This product is provided in the form of Tris salt.
    FITC-Ahx-β-Amyloid (1-42), (rat/mouse) tris
  • HY-P1891
    β-Amyloid (22-40)

    		Amyloid-β Neurological Disease
    β-Amyloid (22-40) is a peptide fragment of β-Amyloid.
    β-Amyloid (22-40)
  • HY-171349
    Amyloid-β-IN-3

    		γ-secretase Amyloid-β Neurological Disease
    Amyloid-β-IN-3 (EX.113) is a selective γ-secretase inhibitor. Amyloid-β-IN-3 inhibits Aβ42 secretion in H4 cells with an EC50 value of 148 nM. Amyloid-β-IN-3 regulates the γ-secretase catalytic activity to decrease Aβ42 production, thereby alleviating neurotoxicity caused by Aβ deposition. Amyloid-β-IN-3 is promising for research of Alzheimer's disease (AD) .
    Amyloid-β-IN-3
  • HY-P4867
    β Amyloid (1-42) (scrambled)

    		Amyloid-β Neurological Disease
    β Amyloid (1-42) (scrambled) is a negative control of β-Amyloid (1-42), human (HY-P1363A) .
    β Amyloid (1-42) (scrambled)
  • HY-P1362A
    β-Amyloid (42-1), human TFA

    amyloid β peptide (42-1)(human) TFA

    		 Amyloid-β Neurological Disease
    β-Amyloid (42-1), human TFA is the inactive form of Amyloid β Peptide (1-42). β-Amyloid (42-1), human TFA is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease .
    β-Amyloid (42-1), human TFA
  • HY-103538
    JLK-6

    		Amyloid-β Neurological Disease
    JLK-6 markedly reduce the production of amyloid β-peptide (Aβ) by amyloid-β Precursor protein (APP) expressing HEK293 cells by affecting the γ-secretase cleavage of APP, with no effect on the cleavage of the Notch receptor .
    JLK-6
  • HY-P1522
    β-Amyloid (29-40)

    amyloid beta-protein(29-40)

    		 Amyloid-β Neurological Disease
    β-Amyloid (29-40) is a fragment of Amyloid-β peptide.
    β-Amyloid (29-40)
  • HY-P0265AS
    β-Amyloid-15N (1-40) TFA

    amyloid Beta-peptide-15N (1-40) (human) TFA; amyloid β-peptide-15N (1-40) (human) TFA

    		 Amyloid-β Neurological Disease
    β-Amyloid- 15N (1-40) (TFA) is the 15N-labledβ-Amyloid (1-40) (TFA). β-Amyloid (1-40) is a primary protein in plaques found in the brains of patients with Alzheimer's disease .
    β-Amyloid-15N (1-40) TFA
  • HY-P1053
    β-Amyloid (10-20)

    		Amyloid-β Neurological Disease
    β-Amyloid (10-20) is a fragment of Amyloid-β peptide and maybe used in the research of neurological disease .
    β-Amyloid (10-20)
  • HY-W440555
    4-Sulfocalix[4]arene

    para-Sulfonatocalix[n]arene

    		 Amyloid-β Neurological Disease
    4-Sulfocalix[4]arene (para-Sulfonatocalix[n]arene) is a amyloid-beta 42 binder with a Kd of 5.39 M. 4-Sulfocalix[4]arene can inhibit amyloid β-peptide fibrillation and reduce amyloid cytotoxicity .
    4-Sulfocalix[4]arene
  • HY-P2562
    β-Amyloid (1-38), mouse, rat

    		Amyloid-β Neurological Disease
    β-Amyloid (1-38), mouse, rat is composed of 38 aa (1-38 residues of the Aβ peptide) and is the primary component of the amyloid plaques of Alzheimer’s disease .
    β-Amyloid (1-38), mouse, rat
  • HY-P3859
    Cys-Gly-Lys-Arg-Amyloid β-Protein (1-42)

    		Amyloid-β Neurological Disease
    Cys-Gly-Lys-Arg-Amyloid β-Protein (1-42) is a peptide fragment of amyloid β-protein (Aβ). Cys-Gly-Lys-Arg-Amyloid β-Protein (1-42) can be used in research of Alzheimer's disease .
    Cys-Gly-Lys-Arg-Amyloid β-Protein (1-42)
  • HY-P1363S1
    β-Amyloid (1-42), human, Ala(13C3,15N) TFA

    		Isotope-Labeled Compounds Amyloid-β Neurological Disease
    β-Amyloid (1-42), human, Ala( 13C3, 15N) TFA is the 13C and 15N-labeled β-Amyloid (1-42), human (HY-P1363A). β-Amyloid (1-42) (Amyloid β-peptide (1-42)), human, a 42-amino acid peptide that has not been treated with HFIP, is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human, after being monomericized by HFIP and dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4 °C, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37 °C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death .
    β-Amyloid (1-42), human, Ala(13C3,15N) TFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: